Table 4.
Adverse events associated with ATZ + BV treatment.
| Adverse Events | Grade 1 or 2 | Grade 3 | Any Grade (%) |
|---|---|---|---|
| Pyrexia | 12 | 0 | 12 (42.9) |
| Fatigue | 4 | 5 | 9 (32.1) |
| Increased TSH | 7 | 0 | 7 (25.0) |
| Liver disfunction | 6 | 1 * | 7 (25.0) |
| Renal disfunction | 6 | 0 | 6 (21.4) |
| Rash | 4 | 1 * | 5 (17.9) |
| Proteinuria | 3 | 1 | 4 (14.3) |
| Decreased appetite | 3 | 1 | 4 (14.3) |
| Hypertension | 3 | 1 | 4 (14.3) |
| Stomatitis | 3 | 0 | 3 (10.7) |
| Ascites | 3 | 0 | 3 (10.7) |
| Edema | 3 | 0 | 3 (10.7) |
| Diarrhea | 2 | 1 | 3 (10.7) |
| Dicreased TSH | 2 | 0 | 2 (7.1) |
| Palmar–plantar erythrodysesthesia | 2 | 0 | 2 (7.1) |
| Oral mucositis | 0 | 2 * | 2 (7.1) |
| Heart failure | 1 | 0 | 1 (3.6) |
| Infusion reaction | 1 | 0 | 1 (3.6) |
| Acute adrenal insufficiency | 0 | 1 * | 1 (3.6) |
| Hemophagocytic syndrome | 0 | 1 * | 1 (3.6) |
Values are expressed as a number in grade 1 and 2 and grade 3 categories. Values are expressed as number (%) in any grade category. * These cases were treated with steroid therapy due to severe irAEs. TSH—thyroid-stimulating hormone; ATZ—atezolizumab; BEV—bevacizumab; irAE—immune-related adverse event.